5 completed, 3 active not recruiting, 2 terminated, 1 recruiting. 7 Phase 3, 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 3, Active not recruiting 2, Recruiting 1, Unknown 1 |
| Phase 2 | 6 | Active not recruiting 3, Completed 2, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow nilutamide: new trials by email Literature Review of nilutamide trials Research Report on nilutamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease - Prostate Cancer, Oligometastasis | Phase 2 / Phase 3 | Active not recruiting | VA Office of Research and Development | 378 | 2021-07-01 | 2026-10-19 |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Abiraterone, Bicalutamide, Degarelix - Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 1273 | 2018-09-24 | 2026-10-08 |
| Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery Bicalutamide, Degarelix, Docetaxel - Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7 | Phase 2 / Phase 3 | Active not recruiting | NRG Oncology | 612 | 2017-04-05 | 2026-09-14 |
| Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer Abiraterone Acetate, Bicalutamide, Degarelix - Prostate Adenocarcinoma, Recurrent Prostate Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 310 | 2013-02-05 | 2026-08-11 |
| Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer Nilutamide, Dasatinib - Prostate Cancer | Phase 2 | Terminated | Duke University | 57 | 2009-05-01 | 2014-10-29 |
| Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer leuprolide acetate, goserelin acetate, bicalutamide - Adenocarcinoma of the Prostate, Recurrent Prostate Cancer | Phase 1 | Terminated | National Cancer Institute (NCI) | 24 | 2007-09-01 | 2013-01-07 |
| Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy Androgen suppression, radiotherapy, Androgen suppression, radiotherapy, iodine 125 brachytherapy - Prostate Cancer | Phase 3 | Unknown | University of British Columbia | 400 | 2004-05-01 | 2014-03-17 |
| S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer bicalutamide, estramustine, etoposide - Prostate Cancer | Phase 2 | Completed | SWOG Cancer Research Network | 41 | 2001-12-01 | 2013-07-16 |
| Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer aldesleukin, recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine - Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 2000-06-01 | 2015-04-29 | |
| Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer bicalutamide, buserelin, cyproterone acetate - Prostate Cancer | Phase 3 | Completed | NCIC Clinical Trials Group | 1386 | 1999-01-05 | 2021-06-23 |
| Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer Bicalutamide, Doxorubicin hydrochloride, Estramustine Phosphate Sodium - Prostate Cancer | Phase 3 | Completed | M.D. Anderson Cancer Center | 306 | 1996-08-01 | 2018-10-31 |
| Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer bicalutamide, buserelin, flutamide - Prostate Cancer | Phase 3 | Completed | NCIC Clinical Trials Group | 361 | 1995-02-08 | 2020-04-03 |
Prostatic Neoplasms (11) · Bulbo-Spinal Atrophy, X-Linked (1) · Neoplasm Metastasis (1)
M.D. Anderson Cancer Center (2) · NCIC Clinical Trials Group (2) · National Cancer Institute (NCI) (2) · SWOG Cancer Research Network (2) · Duke University (1) · NRG Oncology (1) · University of British Columbia (1) · VA Office of Research and Development (1)
United States (9) · Canada (4) · Chile (1) · Colombia (1) · Mexico (1) · Puerto Rico (1) · Switzerland (1)
Christopher Logothetis (2) · Abhishek Solanki, MD MS (1) · Brian Chapin (1) · Celestia S. Higano, MD (1) · Daniel George, MD (1) · David C. Smith, MD (1) · Laurence H. Klotz, MD (1) · Malcolm D. Mason, MD (1) · Mark D Hurwitz (1) · Padraig R. Warde, MB, MRCPI, FRCPC (1) · Patricia Lillis-Hearne, MD (1) · Philip M. Arlen, MD (1) · Randall E. Millikan, MD, PhD (1) · Richard R. Whittington, MD (1) · Srinivasan Vijayakumar, MD (1)
PMID 16006888, PMID 18628467, PMID 19029421, PMID 22056152, PMID 22931259, PMID 25691677, PMID 25732157, PMID 26014295, PMID 28433432, PMID 28581398, PMID 30245169, PMID 33390282
I01CX002277 (1), P30CA016672 (1), U10CA032102 (1), U10CA180868 (1), U10CA180888 (1)